DEFA14A: NovaBay Pharmaceuticals Receives ISS Support for Asset Sale and Liquidation Proposals

Institutional Shareholder Services (ISS) recommends NovaBay stockholders vote in favor of the proposed sale of its Avenova business and the subsequent liquidation of the company.

Summary

• NovaBay Pharmaceuticals is seeking stockholder approval to sell its Avenova business to PRN Physician Recommended Nutriceuticals, LLC for $11.5 million in cash, subject to adjustments.
• The company also proposes a voluntary liquidation and dissolution, where remaining assets will be distributed to stockholders after settling obligations.
• Institutional Shareholder Services (ISS), a prominent proxy advisory firm, supports both the asset sale and the liquidation proposals.
• ISS believes the asset sale is the best option to maximize shareholder value and the cash consideration provides liquidity and certainty.
• The Special Meeting of Stockholders to vote on these proposals will be held virtually on November 22, 2024.
• Stockholders as of October 15, 2024 are eligible to vote.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is liquidating, the asset sale is viewed as a positive step to maximize shareholder value, and the support from ISS adds confidence. However, the end of the company's operations tempers the overall sentiment.

Positives

• The proposed asset sale provides a cash infusion of $11.5 million, subject to adjustments.
• ISS support indicates a positive outlook for the proposals' approval.
• The cash consideration from the sale offers liquidity and certainty for shareholders.
• The asset sale is viewed as the best available option to maximize shareholder value.

Negatives

• The company is planning to liquidate and dissolve after the asset sale, indicating the end of its operations.
• There is a potential downside risk if the proposals are not approved by shareholders.

Risks

• There is a risk that stockholders may not approve the asset sale or the liquidation proposals.
• The actual proceeds from the asset sale may be subject to adjustments.
• The liquidation process involves uncertainties regarding the final distribution to stockholders.
• The company's future is dependent on the successful completion of the asset sale and liquidation.

Future Outlook

The company intends to sell its Avenova business, wind down operations, settle remaining obligations, and distribute any remaining proceeds to stockholders, subject to the discretion of the Board of Directors.

Management Comments

• The NovaBay Board of Directors unanimously supports the Asset Sale Proposal and the Dissolution Proposal.

Industry Context

The sale of the Avenova business and subsequent liquidation suggests a strategic shift for NovaBay, possibly due to challenges in the eyecare market or a decision to focus on other opportunities. This is not uncommon in the pharmaceutical industry where companies may divest assets to streamline operations or maximize shareholder value.

Comparison to Industry Standards

• The sale of a business unit for a fixed cash price is a common transaction in the pharmaceutical industry, similar to other companies divesting non-core assets.
• The decision to liquidate and dissolve the company is less common, suggesting that the company may not have viable alternatives for its remaining assets or operations.
• Comparable companies that have divested assets include those that have sold off specific product lines or business units to focus on core competencies or to raise capital.
• The $11.5 million sale price will need to be compared to the book value of the Avenova business and the potential value of the company's remaining assets to determine if it is a fair price.

Stakeholder Impact

• Shareholders will receive proceeds from the asset sale and liquidation, if approved.
• Employees of the Avenova business may be impacted by the sale to PRN.
• Customers of Avenova products will likely see a change in ownership and distribution.

Next Steps

• Stockholders will vote on the asset sale and liquidation proposals at the Special Meeting on November 22, 2024.
• If approved, the company will proceed with the sale of the Avenova business to PRN.
• Following the sale, the company will begin the process of liquidation and dissolution.

Key Dates

Keywords

NovaBay Pharmaceuticals, Avenova, Asset Sale, Liquidation, Dissolution, PRN, ISS, Shareholders, Proxy Vote